CN112367984B - Stat3抑制剂 - Google Patents

Stat3抑制剂 Download PDF

Info

Publication number
CN112367984B
CN112367984B CN201980041259.1A CN201980041259A CN112367984B CN 112367984 B CN112367984 B CN 112367984B CN 201980041259 A CN201980041259 A CN 201980041259A CN 112367984 B CN112367984 B CN 112367984B
Authority
CN
China
Prior art keywords
cancer
disease
certain embodiments
pharmaceutical composition
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980041259.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN112367984A (zh
Inventor
索非亚·德亚加瓦尔·维德
W·E·布塔
W·R·小坎特雷尔
大卫·约翰·泰迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tweedy Therapeutics Inc
Baylor College of Medicine
Original Assignee
Tweedy Therapeutics Inc
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tweedy Therapeutics Inc, Baylor College of Medicine filed Critical Tweedy Therapeutics Inc
Publication of CN112367984A publication Critical patent/CN112367984A/zh
Application granted granted Critical
Publication of CN112367984B publication Critical patent/CN112367984B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
    • C07C303/40—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polymerisation Methods In General (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201980041259.1A 2018-04-19 2019-04-18 Stat3抑制剂 Active CN112367984B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862659872P 2018-04-19 2018-04-19
US62/659,872 2018-04-19
US201962793491P 2019-01-17 2019-01-17
US62/793,491 2019-01-17
PCT/US2019/028135 WO2019204614A1 (en) 2018-04-19 2019-04-18 Stat3 inhibitors

Publications (2)

Publication Number Publication Date
CN112367984A CN112367984A (zh) 2021-02-12
CN112367984B true CN112367984B (zh) 2024-05-10

Family

ID=68240338

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980041259.1A Active CN112367984B (zh) 2018-04-19 2019-04-18 Stat3抑制剂

Country Status (18)

Country Link
US (2) US11826315B2 (https=)
EP (2) EP3773537B1 (https=)
JP (1) JP7411315B2 (https=)
KR (1) KR102792113B1 (https=)
CN (1) CN112367984B (https=)
AU (1) AU2019255755B2 (https=)
BR (1) BR112020021329A2 (https=)
DK (1) DK3773537T3 (https=)
ES (1) ES2911428T3 (https=)
HU (1) HUE059318T2 (https=)
IL (1) IL278112B2 (https=)
MX (1) MX2020011065A (https=)
MY (1) MY207195A (https=)
PH (1) PH12020551728A1 (https=)
PL (1) PL3773537T3 (https=)
PT (1) PT3773537T (https=)
SG (1) SG11202010347XA (https=)
WO (1) WO2019204614A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7411315B2 (ja) * 2018-04-19 2024-01-11 トゥヴァルディ セラピューティクス，インク． Ｓｔａｔ３阻害剤
CN114761405A (zh) * 2019-11-29 2022-07-15 南京明德新药研发有限公司 抗hbv的1,7-萘啶类化合物
JP2023504194A (ja) * 2019-12-03 2023-02-01 ベイラー カレッジ オブ メディスン インスリン耐性における使用方法のための治療化合物
JP2023520273A (ja) * 2020-01-24 2023-05-17 トゥヴァルディ セラピューティクス，インク． 治療化合物、製剤、およびその使用
CN114286684B (zh) * 2020-07-27 2024-01-05 华中科技大学 与stat3相关的疾病的预防和/或治疗
AR128676A1 (es) * 2022-03-01 2024-06-05 Tvardi Therapeutics Inc Compuestos terapéuticos, formulaciones, uso y método de preparación
US20250170079A1 (en) * 2022-03-04 2025-05-29 Tvardi Therapeutics, Inc. Combinations of stat-inhibitors and immune checkpoint inhibitors for the treatment and/or management of cancer
CA3254067A1 (en) 2022-06-15 2023-12-21 Tvardi Therapeutics, Inc. STAT3 INHIBITOR MEDICINES
TW202412749A (zh) * 2022-07-21 2024-04-01 美商特梵迪治療股份有限公司 治療性化合物、調配物、及其用途
EP4633620A1 (en) * 2022-12-12 2025-10-22 Tvardi Therapeutics, Inc. Stat3 inhibitors for use in the treatment of non-viral liver cancer
WO2025184497A1 (en) * 2024-02-29 2025-09-04 Tvardi Therapeutics, Inc. Stat3 inhibitors for use in the treatment of cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009149192A1 (en) * 2008-06-04 2009-12-10 Baylor College Of Medicine Stat3 inhibitors
CN103288787A (zh) * 2007-09-10 2013-09-11 波士顿生物技术公司 新的stat3 途径抑制剂和癌症干细胞抑制剂

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4279909A (en) 1980-02-13 1981-07-21 Fujisawa Pharmaceutical Co., Ltd. Antiallergic method
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6492428B1 (en) 2000-07-26 2002-12-10 The Picower Institute For Medical Research Compounds having MIF antagonist activity
US6197749B1 (en) 1997-10-29 2001-03-06 Ajinomoto Co., Inc. Method of suppressing immune responses by reducing intracellular content of glutathione in macrophages and monocytes
CA2413878A1 (en) 2000-06-20 2001-12-27 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders
JP2005522457A (ja) 2002-02-26 2005-07-28 ノース ショア−ロング アイランド ジューイッシュ リサーチ インスティチュート 脳ムスカリン性レセプターの刺激による炎症性サイトカイン産生の阻害
WO2005026134A1 (en) 2003-09-17 2005-03-24 Novartis Ag Organic compounds
US20050287664A1 (en) 2004-05-27 2005-12-29 Ming-Ji Fann Cellular proliferation control factors
US20060148715A1 (en) 2004-12-20 2006-07-06 Baylor College Of Medicine Structural requirements for STAT3 binding and recruitment to phosphotyrosine ligands
US20100035793A1 (en) 2005-07-27 2010-02-11 Cheh Peng Lim Modulators
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
CA2636909A1 (en) 2006-01-13 2007-07-26 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production with tanshinones
WO2007136858A2 (en) 2006-05-19 2007-11-29 H. Lee Moffitt Cancer Center & Research Institute Small molecule inhibitors of stat3 with anti-tumor activity
US20090264353A1 (en) 2007-10-19 2009-10-22 Santaris Pharma A/S Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease
WO2009038784A1 (en) 2007-09-21 2009-03-26 Amgen Inc. Triazole fused heteroaryl compounds as p38 kinase inhibitors
GB2463514C (en) 2008-09-11 2018-09-26 Galapagos Nv Imidazolidine compounds and uses therefor
WO2010080581A2 (en) 2008-12-19 2010-07-15 The Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno Valproic acid, derivatives, analogues, and compositions including same and methods for their therapeutic use
US8557805B2 (en) 2008-12-29 2013-10-15 Takeda Pharmaceutical Company Limited Fused ring compound and use thereof
US9891213B2 (en) 2009-01-12 2018-02-13 The Board Of Trustees Of The Leland Stanford Junior University Granulocyte-based methods for detecting and monitoring immune system disorders
CA2781706A1 (en) * 2009-11-24 2011-06-03 The Ohio State University Transcription factor inhibitors and related compositions, formulations and methods
FR2962649B1 (fr) 2010-07-19 2025-10-24 Conservatoire Nat Arts Et Metiers Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide
US20140371188A1 (en) 2011-11-23 2014-12-18 University Of Iowa Research Foundation Compositions and methods for inhibiting muscle atrophy and inducing muscle hypertrophy
EP2708535A1 (en) 2012-05-11 2014-03-19 Les Laboratoires Servier Agents for treating disorders involving modulation of ryanodine receptors
CN102766103B (zh) * 2012-07-24 2014-12-10 齐鲁制药有限公司 2-硫代-4-胺基-1-萘酚衍生物、其制备方法和用途
AU2014290363B2 (en) * 2013-07-18 2019-02-21 Baylor College Of Medicine Methods and compositions for treatment of fibrosis
AU2014290368B2 (en) 2013-07-18 2019-07-11 Baylor College Of Medicine Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia
US20150031714A1 (en) 2013-07-18 2015-01-29 Baylor College Of Medicine Methods and compositions for prevention of allergic reaction
WO2017083719A1 (en) * 2015-11-13 2017-05-18 William Marsh Rice University Transition metal free methods of synthesis of biaryl compounds
JP7411315B2 (ja) * 2018-04-19 2024-01-11 トゥヴァルディ セラピューティクス，インク． Ｓｔａｔ３阻害剤
US11026905B2 (en) * 2018-04-19 2021-06-08 Tvardi Therapeutics, Inc. STAT3 inhibitors
JP2023520273A (ja) * 2020-01-24 2023-05-17 トゥヴァルディ セラピューティクス，インク． 治療化合物、製剤、およびその使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103288787A (zh) * 2007-09-10 2013-09-11 波士顿生物技术公司 新的stat3 途径抑制剂和癌症干细胞抑制剂
WO2009149192A1 (en) * 2008-06-04 2009-12-10 Baylor College Of Medicine Stat3 inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
蒋荣海.《药物化学基础》.中国医药科技出版社,2001,第134页. *

Also Published As

Publication number Publication date
CN112367984A (zh) 2021-02-12
ES2911428T3 (es) 2022-05-19
MY207195A (en) 2025-02-05
KR102792113B1 (ko) 2025-04-04
KR20210011925A (ko) 2021-02-02
JP7411315B2 (ja) 2024-01-11
US20240058284A1 (en) 2024-02-22
US11826315B2 (en) 2023-11-28
AU2019255755A1 (en) 2020-12-03
BR112020021329A2 (pt) 2021-04-27
IL278112B2 (en) 2023-07-01
JP2021521243A (ja) 2021-08-26
EP3773537A1 (en) 2021-02-17
US20210114980A1 (en) 2021-04-22
IL278112B1 (en) 2023-03-01
PL3773537T3 (pl) 2022-05-23
PT3773537T (pt) 2022-04-19
AU2019255755B2 (en) 2024-07-25
MX2020011065A (es) 2021-01-20
EP4070790A1 (en) 2022-10-12
SG11202010347XA (en) 2020-11-27
HUE059318T2 (hu) 2022-11-28
CA3097403A1 (en) 2019-10-24
PH12020551728A1 (en) 2021-06-14
IL278112A (https=) 2020-12-31
EP3773537B1 (en) 2022-03-23
EP3773537A4 (en) 2021-05-26
DK3773537T3 (en) 2022-04-25
WO2019204614A1 (en) 2019-10-24

Similar Documents

Publication Publication Date Title
CN112367984B (zh) Stat3抑制剂
US11026905B2 (en) STAT3 inhibitors
EP2121692A1 (en) Substituted heterocycles as janus kinase inhibitors
CN117886813A (zh) Shp2磷酸酶变构抑制剂
JP7681059B2 (ja) ヤーヌスキナーゼ（ｊａｋ）ファミリー阻害剤及びその調製と使用
US20240182470A1 (en) Krasg12c mutant protein inhibitor, prearation and use thereof
WO2022095910A1 (zh) 用作激酶抑制剂的化合物及其应用
JP2023520595A (ja) ピラゾロピリダジノン化合物、その医薬組成物及びその用途
WO2019204427A1 (en) Methods for measuring and stabilizing stat3 inhibitors
CN116023368A (zh) Crbn免疫调节剂
WO2023143147A1 (zh) 一种哒嗪并吡啶酮类化合物、其药物组合物及应用
CN120302969A (zh) 可用作iap抑制剂的化合物和组合物
CN119365474A (zh) Stat3抑制剂的前药
TWI321566B (en) Pyrido[2,3-d]pyrimidine derivatives, preparation thereof, therapeutic use thereof
CA2992674A1 (en) Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent
CA3097403C (en) Stat3 inhibitors
HK40073672A (en) Stat3 inhibitors
EA043779B1 (ru) Ингибиторы stat3
HK40038526B (en) Stat3 inhibitors
HK40038526A (en) Stat3 inhibitors
HK40072576B (zh) 用作激酶抑制剂的化合物及其应用
TW202430505A (zh) 萘醯胺類化合物、其製備方法及其應用
HK40072576A (en) Compound used as kinase inhibitor and use thereof
CN121419769A (zh) 异双功能化合物及其使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant